Ananthasubramaniam Rajagopal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ananthasubramaniam Rajagopal has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Amit Gupta
Department of Nephrology, Apollomedics Superspeciality Hospital, Lucknow, Uttar Pradesh, India
1 shared publication - Amol Mahaldar
Vision and Manipal Hospitals, Mapuca 403507, India
1 shared publication - Anita Saxena
Department of Nephrology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow 226014, India
1 shared publication - Chakko Jacob
Department of Nephrology, Christian Medical College Vellore, Ranipet, India
1 shared publication - Ilangovan Veerappan
Department of Nephrology, KG Hospital and Postgraduate Institute, Coimbatore, Tamil Nadu, India
1 shared publication - Sanjay Srinivasa
Department of Nephrology, Sapthagiri Medical College, Bengaluru, Karnataka, India
1 shared publication
Latest Publications
- Open Access
Enzobiotics—A Novel Therapy for the Elimination of Uremic Toxins in Patients with CKD (EETOX Study): A Multicenter Double-Blind Randomized Controlled Trial
Design, participants, setting, and measurements: Predialysis adult participants with chronic kidney disease (CKD) and mean estimated glomerular filtration rate (eGFR) 20 µg/mL) was 53% for the placebo group and 32% for the enzobiotic group. The corresponding levels for IS risk (threshold >20,000 ng/mL) were 35% and 24% for the placebo and enzobiotic groups, respectively. In the placebo group, eGFR decreased by 7% (Day 90) but remained stable (1.00) in the enzobiotic group. QoL as assessed by the adversity ratio decreased significantly (p = 0.00), highlighting an improvement in the enzobiotic group compared to the placebo group. The predictive equations were as follows: PCS (Day 0 = −5.97 + 0.0453 PC + 2.987 UA − 1.310 Creat; IS (Day 0) = 756 + 1143 Creat + 436.0 Creat2. Conclusion: Enzobiotics significantly reduced the PCS and IS, as well as improved the QoL.
Open AccessEnzobiotics—A Novel Therapy for the Elimination of Uremic Toxins in Patients with CKD (EETOX Study): A Multicenter Double-Blind Randomized Controlled Trial
Design, participants, setting, and measurements: Predialysis adult participants with chronic kidney disease (CKD) and mean estimated glomerular filtration rate (eGFR) 20 µg/mL) was 53% for the placebo group and 32% for the enzobiotic group. The corresponding levels for IS risk (threshold >20,000 ng/mL) were 35% and 24% for the placebo and enzobiotic groups, respectively. In the placebo group, eGFR decreased by 7% (Day 90) but remained stable (1.00) in the enzobiotic group. QoL as assessed by the adversity ratio decreased significantly (p = 0.00), highlighting an improvement in the enzobiotic group compared to the placebo group. The predictive equations were as follows: PCS (Day 0 = −5.97 + 0.0453 PC + 2.987 UA − 1.310 Creat; IS (Day 0) = 756 + 1143 Creat + 436.0 Creat2. Conclusion: Enzobiotics significantly reduced the PCS and IS, as well as improved the QoL.